Thursday - October 22, 2026
FDA Center for Drug Evaluation & Research Issues Warning Letter to Signature Formulations
October 22, 2026
WASHINGTON, Oct. 22 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Signature Formulations LLC from its Center for Drug Evaluation and Research:

* * *

Recipient: Maria C. Esparza, President and CEO, Signature Formulations LLC, 5446 W Rosevelt St. Suite 101, Phoenix, AZ 85043, United States, maria@sigform.com

Issuing Office: Center for Drug Evaluation and Research (CDER), Unit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products